MetaCap

Inogen Inc (INGN)

NASDAQ: INGNHealth CareIndustrial SpecialtiesUSD

5.30-0.12 (-2.21%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

INGN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$137.81M
EPS (TTM)
-$1.21
52-week range
5.05 – 7.67
Day range
5.24 – 5.68
Volume / Avg
351.93K / 315.66K
Beta
—

52-week range

$5.05$7.67

INGN stock today

On Nov 20, INGN ended the session at $5.30, shedding $0.12 (2.21%), versus the S&P 500's 3.70% decline. At this level, INGN sits near the bottom of its 52-week range of $5.05 to $7.67: 30.9% below the high, set on Apr 28, 2026 and 5.1% above the low. INGN is down 21.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 23.0%.

Inogen has posted a net loss over the last twelve months (EPS of -$1.21), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Inogen

Company profile

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories.

Industry
Industrial Specialties
CEO
Mr. Andrew P. Reding
Headquarters
Beverly, MA
Employees
753
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Inogen generated $348.7 million in revenue, up 3.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Inogen reported a net loss of $22.7 million, compared with a loss of $35.9 million a year earlier. Gross margin was 44.2% (down from 46.1%) and operating margin -8.7%.

Inogen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$348.67M$335.70M$315.66M$377.24M$358.00M
Growth+3.86%+6.35%-16.32%+5.37%+16.05%
Net income$-22.75M$-35.89M$-102.45M$-83.77M$-6.33M
EPS (diluted)$-0.86$-1.52$-4.42$-3.67$-0.28

Analyst forecast

Forecast

Consensus (2 analysts)

strong_buy

Avg. price target

$10.75+102.83%

  • Strong buy 1
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.50High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.20 vs —

INGN news

All INGN news

Inogen peers

Health Care sector
INGN peer companies
CompanyPrice% ChgMarket capCompare
BOOMDMC Global Inc.6.70-6.94%$137.62Mvs INGN
AMROAmaero Inc.5.80+3.57%$160.76Mvs INGN
HDSNHudson Technologies Inc.3.91-4.17%$164.57Mvs INGN
VIRCVirco Manufacturing Corporation5.91-1.17%$93.16Mvs INGN
LAKELakeland Industries Inc.8.29-0.48%$82.33Mvs INGN
AGPUAxe Compute Inc.5.71-10.85%$77.94Mvs INGN
NTICNorthern Technologies International Corporation7.38-1.99%$71.09Mvs INGN
OFLXOmega Flex Inc.21.15-2.08%$213.49Mvs INGN

Indexes, lists and sector

Inogen stock FAQ

What is Inogen's stock price today?

INGN last traded at $5.30 as of Nov 20, 4:00 PM EST, down 2.21% on the day. Prices are delayed at least 15 minutes.

Who is Inogen's CEO?

Mr. Andrew P. Reding is the chief executive officer of Inogen Inc, which has about 753 employees.

What is the INGN 52-week high?

The 52-week high for INGN is $7.67 and the 52-week low is $5.05. The stock is currently 30.9% below its high.

Compare INGN